Biotech Values

[rogerm]

Yes many of the popular MDD drugs have seen their sales crash due to generics. But SAGE-217 is the 1st in a different class of antidepressant that stands out for its fast acting effect and the unusually high remission rate obtained. Below is the 89 patient P3 MDD result.

Effect on Depressive Symptoms through end of Treatment (Day 15):

-Treatment with SAGE-217 was associated with a statistically significant mean reduction from baseline in the Hamilton Rating Scale for Depression (HAM-D) total score at Day 15 of 17.6 points compared with a 10.7 point mean reduction associated with placebo (p<0.0001).

-The majority of patients (64%) who received SAGE-217 achieved remission at Day 15 as determined by a HAM-D total score less than or equal to 7 (compared with 23% of patients who received placebo, p=0.0005).

-Other secondary endpoints (e.g., MADRS, CGI-I) were similarly highly significant at Day 15 (p≤0.002).